Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2021.2228
Abstract: Importance It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Objective To assess the safety and efficacy of ticagrelor vs prasugrel… read more here.
Keywords: ticagrelor; analysis; group; randomized clinical ... See more keywords
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Internal Medicine"
DOI: 10.1001/jamainternmed.2018.0783
Abstract: Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer… read more here.
Keywords: iqr; inhibitor; p2y12; ticagrelor ... See more keywords
Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.22597
Abstract: Key Points Question Is dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor associated with better clinical outcomes for patients with acute coronary syndrome treated with coronary artery bypass grafting compared with ASA monotherapy? Findings… read more here.
Keywords: ticagrelor; artery bypass; coronary artery; bypass grafting ... See more keywords
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Association of Nurse Practitioners"
DOI: 10.1002/2327-6924.12438
Abstract: Purpose We review the use of oral antiplatelet (OAP) therapies in acute coronary syndrome (ACS) management for nurse practitioners (NPs), focusing on current guideline recommendations. Data sources Treatment guidelines and clinical articles from PubMed. Conclusions… read more here.
Keywords: clopidogrel; ticagrelor; antiplatelet; management ... See more keywords
Ticagrelor reduces myocardial cell injury induced by myocardial ischemia-reperfusion in diabetic rats by activating JAK2/STAT3.
Sign Up to like & getrecommendations! Published in 2022 at "Cell biology international"
DOI: 10.1002/cbin.11940
Abstract: The treatment of diabetic patients with myocardial infarction is still full of challenges. Diabetes may exacerbate myocardial ischemia/reperfusion (I/R) injury. Ticagrelor alleviates I/R injury. However, the protective effects of ticagrelor on the diabetic myocardium following… read more here.
Keywords: diabetic rats; ticagrelor; myocardial ischemia; jak2 stat3 ... See more keywords
Predictors and long‐term outcomes of in‐hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30089
Abstract: This study evaluated clinical outcomes of switching from clopidogrel to ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The clinical benefit of in‐hospital switching from clopidogrel to ticagrelor in these… read more here.
Keywords: clopidogrel ticagrelor; ticagrelor; clopidogrel; switching ticagrelor ... See more keywords
Better early than later!
Sign Up to like & getrecommendations! Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30201
Abstract: ST‐segment elevation myocardial infarction (STEMI) typically results from a total thrombotic occlusion following a ruptured atherosclerotic plaque. Early recognition and rapid reperfusion with percutaneous coronary intervention (PCI) are critical to salvage myocardium and prevent subsequent… read more here.
Keywords: time; stemi; ticagrelor; difference ... See more keywords
Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1616
Abstract: Dual antiplatelet therapy (DAPT) is standard in acute coronary heart disease but confers a bleeding risk. To compare the effects of ticagrelor‐monotherapy with ticagrelor‐based DAPT on hemostatic system activation, we conducted a randomized controlled trial… read more here.
Keywords: trial; ticagrelor; ticagrelor based; effects ticagrelor ... See more keywords
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2797
Abstract: Comparative effectiveness evaluation of newer P2Y12 inhibitors (prasugrel and ticagrelor) compared with clopidogrel after acute coronary syndrome (ACS) is limited in real‐world US populations. The objective of this study was to evaluate cardiovascular events based… read more here.
Keywords: ticagrelor; prasugrel clopidogrel; clopidogrel; comparative effectiveness ... See more keywords
Periprocedural Myocardial Injury in High-Risk Patients with Non-ST-Elevation Myocardial Infarction Pre-Treated with Ticagrelor for Less or More than 6 Hours Before PCI.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2014
Abstract: We assessed the impact on periprocedural myocardial injury of a ticagrelor loading dose (LD) given less or more than 6 hours before percutaneous coronary intervention (PCI) in non-ST-elevation myocardial infarction (NSTEMI) patients at high-risk. All… read more here.
Keywords: treated ticagrelor; periprocedural myocardial; pre treated; myocardial injury ... See more keywords
A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2239
Abstract: To compare the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) treated with primary percutaneous coronary intervention (PPCI). 3,528 consecutive patients with ACS treated with PPCI were divided into… read more here.
Keywords: ticagrelor; ticagrelor clopidogrel; clopidogrel patients; clopidogrel ... See more keywords